OBJECTIVE: The efficiency of cell therapy is limited by poor cell survival and engraftment. Here, we studied the effect of the growth hormone-releasing hormone agonist, JI-34, on mesenchymal stem cell (MSC) survival and angiogenic therapy in a mouse model of critical limb ischemia. APPROACH AND RESULTS: Mouse bone marrow-derived MSCs were incubated with or without 10(-8) mol/L JI-34 for 24 hours. MSCs were then exposed to hypoxia and serum deprivation to detect the effect of preconditioning on cell apoptosis, migration, and tube formation. For in vivo tests, critical limb ischemia was induced by femoral artery ligation. After surgery, mice received 50 μL phosphate-buffered saline or with 1×10(6) MSCs or with 1×10(6) JI-34-reconditioned MSCs. Treatment of MSCs with JI-34 improved MSC viability and mobility and markedly enhanced their capability to promote endothelial tube formation in vitro. These effects were paralleled by an increased phosphorylation and nuclear translocation of signal transducer and activator of transcription 3. In vivo, JI-34 pretreatment enhanced the engraftment of MSCs into ischemic hindlimb muscles and augmented reperfusion and limb salvage compared with untreated MSCs. Significantly more vasculature and proliferating CD31(+) and CD34(+) cells were detected in ischemic muscles that received MSCs treated with JI-34. CONCLUSIONS: Our studies demonstrate a novel role for JI-34 to markedly improve therapeutic angiogenesis in hindlimb ischemia by increasing the viability and mobility of MSCs. These findings support additional studies to explore the full potential of growth hormone-releasing hormone agonists to augment cell therapy in the management of ischemia.
OBJECTIVE: The efficiency of cell therapy is limited by poor cell survival and engraftment. Here, we studied the effect of the growth hormone-releasing hormone agonist, JI-34, on mesenchymal stem cell (MSC) survival and angiogenic therapy in a mouse model of critical limb ischemia. APPROACH AND RESULTS:Mouse bone marrow-derived MSCs were incubated with or without 10(-8) mol/L JI-34 for 24 hours. MSCs were then exposed to hypoxia and serum deprivation to detect the effect of preconditioning on cell apoptosis, migration, and tube formation. For in vivo tests, critical limb ischemia was induced by femoral artery ligation. After surgery, mice received 50 μL phosphate-buffered saline or with 1×10(6) MSCs or with 1×10(6) JI-34-reconditioned MSCs. Treatment of MSCs with JI-34 improved MSC viability and mobility and markedly enhanced their capability to promote endothelial tube formation in vitro. These effects were paralleled by an increased phosphorylation and nuclear translocation of signal transducer and activator of transcription 3. In vivo, JI-34 pretreatment enhanced the engraftment of MSCs into ischemic hindlimb muscles and augmented reperfusion and limb salvage compared with untreated MSCs. Significantly more vasculature and proliferating CD31(+) and CD34(+) cells were detected in ischemic muscles that received MSCs treated with JI-34. CONCLUSIONS: Our studies demonstrate a novel role for JI-34 to markedly improve therapeutic angiogenesis in hindlimb ischemia by increasing the viability and mobility of MSCs. These findings support additional studies to explore the full potential of growth hormone-releasing hormone agonists to augment cell therapy in the management of ischemia.
Authors: Rosemeire M Kanashiro-Takeuchi; Lauro M Takeuchi; Ferenc G Rick; Raul Dulce; Adriana V Treuer; Victoria Florea; Claudia O Rodrigues; Ellena C Paulino; Konstantinos E Hatzistergos; Sarah M Selem; Daniel R Gonzalez; Norman L Block; Andrew V Schally; Joshua M Hare Journal: Proc Natl Acad Sci U S A Date: 2011-12-27 Impact factor: 11.205
Authors: Barbara Ludwig; Christian G Ziegler; Andrew V Schally; Claudius Richter; Anja Steffen; Normund Jabs; Richard H Funk; Mathias D Brendel; Norman L Block; Monika Ehrhart-Bornstein; Stefan R Bornstein Journal: Proc Natl Acad Sci U S A Date: 2010-06-28 Impact factor: 11.205
Authors: Jay H Traverse; Timothy D Henry; Stephen G Ellis; Carl J Pepine; James T Willerson; David X M Zhao; John R Forder; Barry J Byrne; Antonis K Hatzopoulos; Marc S Penn; Emerson C Perin; Kenneth W Baran; Jeffrey Chambers; Charles Lambert; Ganesh Raveendran; Daniel I Simon; Douglas E Vaughan; Lara M Simpson; Adrian P Gee; Doris A Taylor; Christopher R Cogle; James D Thomas; Guilherme V Silva; Beth C Jorgenson; Rachel E Olson; Sherry Bowman; Judy Francescon; Carrie Geither; Eileen Handberg; Deirdre X Smith; Sarah Baraniuk; Linda B Piller; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari Journal: JAMA Date: 2011-11-14 Impact factor: 56.272
Authors: Nikolina Dioufa; Andrew V Schally; Ioulia Chatzistamou; Evi Moustou; Norman L Block; Gary K Owens; Athanasios G Papavassiliou; Hippokratis Kiaris Journal: Proc Natl Acad Sci U S A Date: 2010-10-11 Impact factor: 11.205
Authors: Gábor Földes; Maxime Mioulane; Jamie S Wright; Alexander Q Liu; Pavel Novak; Béla Merkely; Julia Gorelik; Michael D Schneider; Nadire N Ali; Sian E Harding Journal: J Mol Cell Cardiol Date: 2010-11-01 Impact factor: 5.000
Authors: Wei Cheng Liang; Jia Lin Ren; Qiu Xiao Yu; Jian Li; Tsz Kin Ng; Wai Kit Chu; Yong Jie Qin; Kai On Chu; Andrew V Schally; Chi Pui Pang; Sun On Chan Journal: Proc Natl Acad Sci U S A Date: 2020-03-02 Impact factor: 11.205
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Jinfeng Gan; Xiurong Ke; Jiali Jiang; Hongmei Dong; Zhimeng Yao; Yusheng Lin; Wan Lin; Xiao Wu; Shumei Yan; Yixuan Zhuang; Wai Kit Chu; Renzhi Cai; Xianyang Zhang; Herman S Cheung; Norman L Block; Chi Pui Pang; Andrew V Schally; Hao Zhang Journal: Proc Natl Acad Sci U S A Date: 2016-12-07 Impact factor: 11.205